Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 7/20 | 0.53 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.45 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.44 |
| ▸ | FNTA | P49354 | 2/20 | 0.41 |
| ▸ | FNTB | P49356 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.40 |
| ▸ | WDR5 | P61964 | 1/20 | 0.40 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.39 |
| ▸ | KDM5A | P29375 | 1/20 | 0.39 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.39 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24208398 | 0.81 | CCR2 (0.47) | CCR2CYP11B1CYP11B2ABCB11 | |
| SCHEMBL3932992 | 0.78 | CYP11B1 (0.56) | CCR2CYP11B1CYP11B2GPBAR1 | |
| SCHEMBL7169286 | 0.77 | CYP11B1 (0.57) | CYP11B1CYP11B2GPBAR1KDM5AKDM5B | |
| SCHEMBL15795442 | 0.77 | CYP11B1 (0.56) | CYP11B1CYP11B2GPBAR1CYP19A1 | |
| Hydrochloric Acid SCHEMBL28186334 | 0.77 | CYP11B1 (0.54) | CCR2CYP11B1CYP11B2GPBAR1 | |
| SCHEMBL7488391 | 0.77 | CYP11B1 (0.47) | CYP11B1CYP11B2GPBAR1 | |
| SCHEMBL27353030 | 0.76 | CYP11B1 (0.54) | CYP11B1CYP11B2GPBAR1CYP19A1 | |
| SCHEMBL7372692 | 0.76 | CYP19A1 (0.47) | CCR2CYP11B1CYP11B2GPBAR1CYP19A1 | |
| SCHEMBL11495128 | 0.75 | PKM (0.64) | CCR2KDM4EKDM5AKDM2BKDM5B | |
| SCHEMBL6708657 | 0.74 | CYP11B1 (0.72) | CYP11B1CYP11B2FNTAFNTBCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271941-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271941-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | CCR2 2673/4885CYP11B1 2126/4885CYP11B2 2194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.